Ablynx
Ablynx's Overview
Ablynx, a Sanofi company, is a biopharmaceutical company renowned for its pioneering work in the discovery and development of Nanobodies®, a novel class of proprietary therapeutic proteins based on single-domain antibody fragments. Founded in 2001 as a spin-off from VIB and the Vrije Universiteit Brussel (VUB), Ablynx developed a strong pipeline in areas such as immunology, hematology, and oncology. In 2018, Sanofi acquired Ablynx for €3.9 billion, integrating its innovative Nanobody® platform to enhance Sanofi's R&D capabilities in biologics. The Ghent site remains a crucial center of excellence for Nanobody® research and development within Sanofi's global network, contributing to the development of next-generation therapies for various diseases.
Where is Ablynx's Headquarters?
HQ Function
Primary research and development hub for Sanofi's Nanobody® platform, focusing on discovery, engineering, and early development of novel antibody-based therapeutics.
Notable Features:
State-of-the-art laboratories within a major European life sciences cluster (Flanders Biobased Valley/Technologiepark Zwijnaarde), fostering collaboration and innovation.
Work Culture:
Highly scientific and innovative environment, integrated into Sanofi's global R&D culture, emphasizing teamwork, cutting-edge research, and a commitment to developing transformative medicines.
HQ Significance:
Original birthplace and global center of excellence for Nanobody® technology, a unique and versatile platform for drug development acquired by Sanofi for its strategic importance in biologics R&D.
Values Reflected in HQ: Innovation, scientific rigor, collaboration, and patient-centricity, aligned with Sanofi's core values in advancing healthcare solutions.
Location:
As an integral part of Sanofi, Ablynx's innovative Nanobody® technology and the therapeutics derived from it contribute to Sanofi's extensive global R&D pipeline and commercial portfolio. This enables the reach of these advancements to patients worldwide. Sanofi operates in over 100 countries, supporting global clinical trials, manufacturing, and commercialization of medicines, including those originating from the Ablynx platform developed in Ghent.
Street Address:
Technologiepark-Zwijnaarde 21
City:
Ghent
State/Province:
East Flanders
Country:
Belgium
Ablynx's Global Presence
Ghent, East Flanders, Belgium (as part of Sanofi)
Address: Technologiepark-Zwijnaarde 21, 9052 Ghent
Acts as Sanofi's center of excellence for Nanobody® research, leveraging the strong biotech ecosystem in Flanders, Belgium, to drive innovation for Sanofi's global therapeutic pipeline. No other distinct 'Ablynx-branded' office locations exist; further global operational support is integrated within Sanofi's worldwide network.
Buying Intent Signals for Ablynx
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Ablynx
As of April 2025, Ablynx' leadership includes:
Investors of Ablynx
Ablynx has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Since its full integration into Sanofi, executive leadership for Ablynx's former operations is managed within Sanofi's global R&D structure. A significant recent change was the appointment of Dr. Houman Ashrafian as Sanofi's new Head of Research & Development in September 2023, who oversees all R&D activities, including those at the Ghent research site (formerly Ablynx). This followed the transition of the previous R&D head.
Departures
New Appointments:
Technology (Tech Stack) used by Ablynx
Discover the tools Ablynx uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Ablynx Email Formats and Examples
Following its acquisition by Sanofi, employees at the former Ablynx site, now a Sanofi research center, use Sanofi's corporate email system. The most common email format for Sanofi globally is [first].[last]@sanofi.com.
[first].[last]@sanofi.com
Format
john.doe@sanofi.com
Example
85%
Success rate
News and media
Sanofi Press Release • December 7, 2023
Sanofi Highlights R&D Strategy and Pipeline Advancements, Reinforcing Commitment to Nanobody Platform
During its R&D Day, Sanofi showcased its strategic priorities and progress in its research and development pipeline. The company emphasized its commitment to leveraging innovative platforms, including Nanobody® technology originating from Ablynx, to develop differentiated medicines. Several Nanobody-derived molecules are advancing in development for immunological and other serious diseases....more
Sanofi Press Release • April 25, 2024
Sanofi Q1 2024 Results Show Continued Specialty Care Growth, Including Nanobody-based Cablivi
Sanofi reported its first-quarter 2024 financial results, highlighting strong performance in its Specialty Care business. Cablivi® (caplacizumab), a Nanobody-based medicine developed by Ablynx (now part of Sanofi) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), continues to contribute to this growth, demonstrating the ongoing value of the Nanobody platform....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Ablynx, are just a search away.